Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
Why BioCryst (BCRX) Might be Well Poised for a Surge
01:20pm, Thursday, 08'th May 2025
BioCryst (BCRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now?
01:00pm, Thursday, 08'th May 2025
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect?
10:55am, Thursday, 08'th May 2025
The mean of analysts' price targets for BioCryst (BCRX) points to a 61.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors
05:29pm, Monday, 05'th May 2025
BioCryst Pharmaceuticals, Inc. BCRX on Monday reported first-quarter sales of $145.50 million, up 52.7% year over year, beating the consensus of $126.87 million.
BioCryst: Strong Opportunity For A Double With A Proven Therapy
02:05pm, Monday, 05'th May 2025
BioCryst Pharmaceuticals' flagship product ORLADEYO shows remarkable growth, maintaining a persistent upward trajectory since its launch in 2020, and is expected to continue into 2025. Despite heavy r
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript
12:54pm, Monday, 05'th May 2025
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1
09:20am, Monday, 05'th May 2025
BioCryst Pharmaceuticals (BCRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.17 per share a year ago.
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update
07:00am, Monday, 05'th May 2025
—Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitabl
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 02'nd May 2025
RESEARCH TRIANGLE PARK, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted s
BioCryst Appoints Steve Frank to Board of Directors
07:00am, Thursday, 01'st May 2025
RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Fr
BioCryst to Present at Upcoming Investor Conferences
07:00am, Wednesday, 30'th Apr 2025
RESEARCH TRIANGLE PARK, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:05am, Monday, 28'th Apr 2025
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst to Report First Quarter 2025 Financial Results on May 5
07:00am, Monday, 21'st Apr 2025
RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on
How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry
06:25pm, Thursday, 10'th Apr 2025
BioCryst (BCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 04'th Apr 2025
RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted
